MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 527052 | Name: Eprazinone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Eprazinone is a mucolytic and bronchospasm relieving agent.

Chemical Structure

Eprazinone
Eprazinone
CAS#10402-90-1 (free base)

Theoretical Analysis

MedKoo Cat#: 527052

Name: Eprazinone

CAS#: 10402-90-1 (free base)

Chemical Formula: C24H32N2O2

Exact Mass: 380.2464

Molecular Weight: 380.53

Elemental Analysis: C, 75.75; H, 8.48; N, 7.36; O, 8.41

Price and Availability

Size Price Availability Quantity
5g USD 250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
10402-53-6 (2HCl) 10402-90-1 (free base)
Synonym
Eprazinone; Eprazinona; Eprazinonum;
IUPAC/Chemical Name
3-(4-(2-Ethoxy-2-phenylethyl)piperazin-1-yl)-2-methyl-1-phenylpropan-1-one
InChi Key
BSHWLCACYCVCJE-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H32N2O2/c1-3-28-23(21-10-6-4-7-11-21)19-26-16-14-25(15-17-26)18-20(2)24(27)22-12-8-5-9-13-22/h4-13,20,23H,3,14-19H2,1-2H3
SMILES Code
O=C(C1=CC=CC=C1)C(C)CN2CCN(CC(OCC)C3=CC=CC=C3)CC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 380.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Krautscheid Y, Senning CJ, Sartori SB, Singewald N, Schuster D, Stuppner H. Pharmacophore modeling, virtual screening, and in vitro testing reveal haloperidol, eprazinone, and fenbutrazate as neurokinin receptors ligands. J Chem Inf Model. 2014 Jun 23;54(6):1747-57. doi: 10.1021/ci500106z. Epub 2014 Jun 12. PubMed PMID: 24849814. 2: Yamamura T, Ohta T, Taira T, Ogawa Y, Sakai Y, Moribe K, Yamamoto K. Effects of automated external lubrication on tablet properties and the stability of eprazinone hydrochloride. Int J Pharm. 2009 Mar 31;370(1-2):1-7. doi: 10.1016/j.ijpharm.2008.11.007. Epub 2008 Nov 18. PubMed PMID: 19059327. 3: Tanabe K, Tsuboi H, Maejima H, Arai S, Katsuoka K. Non-pigmented fixed drug eruption induced by eprazinone hydrochloride. Dermatol Online J. 2005 Dec 1;11(3):25. PubMed PMID: 16409921. 4: Thrall RS, Cloutier MM, Guernsey L, Swayne E, Gionfriddo M. Eprazinone alters lung lavage lipid levels and transtracheal ion transport. Exp Lung Res. 1992 May-Jun;18(3):409-20. PubMed PMID: 1628570. 5: Bury T, Corhay JL, Radermecker MF. [Kinetics of mucus]. Rev Med Liege. 1990 Jan 1;45(1):29-33. French. PubMed PMID: 2305139. 6: Merigot P, Garnier R, Efthymiou ML. [Convulsions with 3 antitussive substituted derivatives of piperazine (zipeprol, eprazinone, eprozinol)]. Ann Pediatr (Paris). 1985 Jun;32(6):504-6, 511. French. PubMed PMID: 4026148. 7: Haber P, Burghuber O, Wolf C. [The bronchospasmolytic effect of eprazinone]. Prax Klin Pneumol. 1985 Feb;39(2):54-8. German. PubMed PMID: 3983078. 8: Faber M, Maucher OM, Stengel R, Goerttler E. [Eprazinone exanthema with subcorneal pustulosis]. Hautarzt. 1984 Apr;35(4):200-3. German. PubMed PMID: 6724909. 9: Ziegler WJ, Behrendt R, Dylla S, Grossberger D, Müller C, Wichard F. [Chronic bronchitis and modification of its clinical symptoms by Eftapan. Experience values from a therapy study of 14,850 patients]. Med Welt. 1983 Jan 7;34(1):23-7. German. PubMed PMID: 6338340. 10: Haguenauer JP, Vautel JM. [Mucitux in the treatment of acute inflammatory states in otorhinolaryngology. Apropos of 60 cases]. J Fr Otorhinolaryngol Audiophonol Chir Maxillofac. 1981 Dec;30(10):677-80. French. PubMed PMID: 6459415. 11: Bauer C. [Proof of eftapan in comparison to bromhexine in children in ambulatory care]. Fortschr Med. 1981 Nov 12;99(42):1769-72. German. PubMed PMID: 7030893. 12: Toffel-Nadolny P, Gielsdorf W. [On the metabolism of eprazinone (author's transl)]. Arzneimittelforschung. 1981;31(4):719-22. German. PubMed PMID: 7195719. 13: Spitzer W. [The efficacy of eprazinone dihydrochloride (Eftapan) in double-blind studies]. Fortschr Med. 1980 Jun 12;98(22):(871-4). German. PubMed PMID: 6997154. 14: Rudkowski Z, Latos T. [Therapy of bronchitis in childhood with Eprazinone (author's transl)]. Padiatr Padol. 1980;15(4):351-64. German. PubMed PMID: 7007990. 15: Kasé Y, Yakushiji T, Seo H, Sakata M, Kito G. [Pharmacological studies on expectorants (author's transl)]. Nihon Yakurigaku Zasshi. 1977 Jul;73(5):605-24. Japanese. PubMed PMID: 924268. 16: Degand P, van der Loo D, Biserte G. [Treatment of bronchial hypersecretion. Demonstration of polyanionic mucins-eprazinone interactions]. Poumon Coeur. 1976;32(4):185-8. French. PubMed PMID: 981126. 17: Kimura K, Ogiya S, Hinoara Y, Takanashi S. [Metabolic fate of Eprazinone hydrochloride. III. Oxidative N-C cleavage of Eprazinone hydrochloride by a rat liver enzyme (author's transl)]. Yakugaku Zasshi. 1975 Aug;95(8):901-5. Japanese. PubMed PMID: 1237604. 18: Takanashi S, Toira Y, Suzuki H, Ogiya S, Sakuma A. [Metabolic fate of Eprazinone hydrochloride. II. Metabolites of Eprazinone hydrochloride in vivo (author's transl)]. Yakugaku Zasshi. 1975 Aug;95(8):897-900. Japanese. PubMed PMID: 1237603. 19: Takanashi S, Hinoara Y, Toira Y, Kamiyama H, Suzuki H. [Metabolic fate of Eprazinone hydrochloride. I. Absorption, distribution, and excretion of Eprazinone hydrochloride in vivo (author's transl)]. Yakugaku Zasshi. 1975 Aug;95(8):1002-9. Japanese. PubMed PMID: 1237598. 20: Matthys H. [Testing of Eprazinone, a new drug with antiobstructive effect on the respiratory tract]. Med Welt. 1975 Mar 14;26(11):520-1. German. PubMed PMID: 1091804.